Study Links T-Cell Fitness to Glofitamab Success in Large B-Cell Lymphoma
A study published in Blood found that the success of the T-cell engager glofitamab in relapsed or refractory large B-cell lymphoma (LBCL) depends heavily on the health and strength of a patient’s T cells. Researchers analyzed patients from the Phase 1/2 NP30179 trial and discovered that patients who responded well to treatment maintained higher levels of […]
Study Links T-Cell Fitness to Glofitamab Success in Large B-Cell Lymphoma Read More »